Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.36 |
| ▸ | CDK9 | P50750 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 3/20 | 0.35 |
| ▸ | MAOB | P27338 | 3/20 | 0.35 |
| ▸ | MET | P08581 | 1/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.34 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.34 |
| ▸ | MAT2A | P31153 | 2/20 | 0.34 |
| ▸ | WNT3A | P56704 | 2/20 | 0.34 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.34 |
| ▸ | F10 | P00742 | 1/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | BCR | P11274 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16775915 | 0.89 | NOTUM (0.40) | NOTUMKDM4EMAOAMAOBIRAK4 | |
| SCHEMBL16776211 | 0.86 | RPS6KA3 (0.43) | WNT3ARPS6KA3ABL1 | |
| SCHEMBL19670571 | 0.83 | NOTUM (0.39) | NOTUMKDM4ECCNT1CDK9MAOA | |
| SCHEMBL16776226 | 0.81 | HTR2C (0.45) | RPS6KA3ABL1BCR | |
| SCHEMBL16776025 | 0.79 | CYP11B2 (0.38) | WNT3A | |
| SCHEMBL16776013 | 0.79 | FGFR4 (0.44) | WNT3ARPS6KA3 | |
| SCHEMBL16776016 | 0.78 | WNT3A (0.40) | WNT3AABL1 | |
| SCHEMBL16776216 | 0.77 | ABL1 (0.34) | WNT3ARPS6KA3ABL1 | |
| SCHEMBL16776210 | 0.77 | BRAF (0.42) | WNT3ARPS6KA3 | |
| SCHEMBL16775868 | 0.76 | CA2 (0.43) | KDM4EABL1BCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | NOTUM 3260/4885KDM4E 950/4885CCNT1 1953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.